Clinical trial
A Phase 1 and Pharmacokinetic Study of Uproleselan (GMI-1271, NSC #801708) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome or Mixed Phenotype Acute Leukemia That Expresses E-selectin Ligand on the Cell Membrane and is in Second or Greater Relapse or That is Refractory to Relapse Therapy
NCT05146739 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 and Pharmacokinetic Study of Uproleselan (GMI-1271, NSC #801708) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome or Mixed Phenotype Acute Leukemia That Expresses E-selectin Ligand on the Cell Membrane and is in Second or Greater Relapse or That is Refractory to Relapse Therapy
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- October 10, 2023
- Completion date
- May 9, 2027
- Enrollment
- 8 (actual)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.
acute myeloid leukemia post cytotoxic therapy, myelodysplastic syndrome post cytotoxic therapy, myeloid leukemia associated with down syndrome, recurrent acute myeloid leukemia, recurrent mixed phenotype acute leukemia, recurrent myelodysplastic syndrome, refractory acute myeloid leukemia, refractory mixed phenotype acute leukemia, refractory myelodysplastic syndrome